» Articles » PMID: 34332176

Effects of α-pyrrolidino-phenone Cathinone Stimulants on Locomotor Behavior in Female Rats

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2021 Jul 31
PMID 34332176
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The α-pyrrolidino-phenone cathinone stimulants first came to widespread attention because of bizarre behavior consequent to the use of α-pyrrolidinopentiophenone (α-PVP, "flakka") reported in popular press. As with other designer drugs, diversification of cathinones has been driven by desirable subjective effects, but also by attempts to stay ahead of legal controls of specific molecules. The α-pyrrolidinohexiophenone (α-PHP) and α-pyrrolidinopropiophenone (α-PPP) compounds have been relatively under-investigated relative to α-PVP and provide a key opportunity to also investigate structure-activity relationships, i.e., how the extension of the alpha carbon chain may affect potency or efficacy. Female rats were used to contrast the effects of α-PHP and α-PPP with those of α-PVP in altering wheel activity and effects on spontaneous locomotion, temperature and intracranial self-stimulation reward. The α-PPP, α-PHP and α-PVP compounds (5, 10 mg/kg, i.p.) suppressed wheel activity. Inhalation of α-PHP or α-PVP also suppressed wheel activity, but for an abbreviated duration compared with the injection route. Spontaneous activity was increased, and brain reward thresholds decreased, in a dose-dependent manner by all three compounds; only small decrements in body temperature were observed. These data show that all three of the α-pyrrolidino-phenone cathinones exhibit significant stimulant-like activity in female rats. Differences were minor and abuse liability is therefore likely to be equivalent for all three α-pyrrolidino-phenones.

Citing Articles

Structure-Activity Relationship of Synthetic Cathinones: An Updated Review.

Nadal-Gratacos N, Pazos M, Pubill D, Camarasa J, Escubedo E, Berzosa X ACS Pharmacol Transl Sci. 2024; 7(9):2588-2603.

PMID: 39296271 PMC: 11406692. DOI: 10.1021/acsptsci.4c00299.


Synthetic Cathinones: Epidemiology, Toxicity, Potential for Abuse, and Current Public Health Perspective.

Chen S, Zhou W, Lai M Brain Sci. 2024; 14(4).

PMID: 38671986 PMC: 11048581. DOI: 10.3390/brainsci14040334.


Adult consequences of repeated nicotine and Δ-tetrahydrocannabinol (THC) vapor inhalation in adolescent rats.

Gutierrez A, Creehan K, Grant Y, Taffe M Psychopharmacology (Berl). 2024; 241(3):585-599.

PMID: 38282127 PMC: 10884208. DOI: 10.1007/s00213-024-06545-5.


Structure-Activity Relationships for a Recently Controlled Synthetic Cathinone Dopamine Transporter Reuptake Inhibitor: α-Pyrrolidinohexiophenone (α-PHP).

Davies R, Nguyen V, Eltit J, Glennon R ACS Chem Neurosci. 2023; 14(14):2527-2536.

PMID: 37406364 PMC: 10670441. DOI: 10.1021/acschemneuro.3c00156.

References
1.
Nguyen J, Grant Y, Taffe M . Paradoxical changes in brain reward status during oxycodone self-administration in a novel test of the negative reinforcement hypothesis. Br J Pharmacol. 2021; 178(18):3797-3812. PMC: 8387405. DOI: 10.1111/bph.15520. View

2.
Malberg J, Seiden L . Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci. 1998; 18(13):5086-94. PMC: 6792575. View

3.
Richman E, Skoller N, Fokum B, Burke B, Hickerson C, Cotes R . α-Pyrrolidinopentiophenone ("Flakka") Catalyzing Catatonia: A Case Report and Literature Review. J Addict Med. 2018; 12(4):336-338. DOI: 10.1097/ADM.0000000000000407. View

4.
Marusich J, Antonazzo K, Wiley J, Blough B, Partilla J, Baumann M . Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology. 2014; 87:206-13. PMC: 4152390. DOI: 10.1016/j.neuropharm.2014.02.016. View

5.
Kenny P, Chen S, Kitamura O, Markou A, Koob G . Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci. 2006; 26(22):5894-900. PMC: 6675212. DOI: 10.1523/JNEUROSCI.0740-06.2006. View